Evotec teams up with Harvard, HHMI on diabetes drugs

Underscoring just how hot academic partnerships have become, Germany's Evotec has forged a research collaboration with Harvard and the Howard Hughes Medical Institute that will focus on new diabetes drugs. Their initial goal will be to identify the physiological mechanisms and targets that regulate beta cell replication. "We are convinced that (the partnership) will lead to the development of a pipeline of exciting drug candidates in diabetes," said Dr. Cord Dohrmann, CSO of Evotec. "Existing therapies have proven largely ineffective against the progression of most degenerative diseases including diabetes. We are enthusiastic about exploring new mechanisms that have the potential to restore beta cell function and produce first-in-class therapeutics for the treatment of diabetes in collaboration with Harvard and HHMI." Evotec release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.